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Long-Term Outcomes Following a Single
Corticosteroid Injection for Trigger Finger
Robert D. Wojahn, MD, Nicholas C. Foeger, MD, PhD, Richard H. Gelberman, MD, and Ryan P. Calfee, MD, MSc
Investigation performed at the Department of Orthopaedic Surgery, Washington University Orthopedics,
Washington University School of Medicine, Saint Louis, Missouri

Background: The outcomes of corticosteroid injection for trigger ﬁnger are well documented only with short-term followup. The purpose of this investigation was to determine the long-term effectiveness of a single injection and to examine
predictors of success up to ten years after injection.
Methods: This case series analyzed 366 ﬁrst-time corticosteroid injections in ﬂexor tendon sheaths from January 2000 to
December 2007 with a minimum follow-up duration of ﬁve years. Two hundred and forty patients (66%) were female, 161
patients (44%) had multiple trigger ﬁngers, and eighty-eight patients (24%) had diabetes at the time of injection. The primary
outcome of treatment failure was deﬁned as subsequent injection or surgical trigger ﬁnger release of the affected digit. Medical
records were reviewed, and any patients without documented failure or a return ofﬁce visit in 2012 to 2013 were contacted by
telephone regarding symptom recurrence and the need for additional treatment. Kaplan-Meier analyses with log-rank test and
Cox regression analysis assessed the effect of baseline patient and disease characteristics on injection success.
Results: Forty-ﬁve percent of patients demonstrated long-term treatment success after a single injection. In the ﬁnal regression
model, the interaction of sex and the number of trigger ﬁngers was the single predictor of treatment success. Exploring this
association revealed a ten-year success rate of 56% for female patients presenting for the ﬁrst time with a trigger ﬁnger compared
with 35% in male patients presenting for the ﬁrst time with a trigger ﬁnger, 39% in female patients with multiple trigger ﬁngers, and
37% in male patients with multiple trigger ﬁngers. Eighty-four percent of treatment failures occurred within the ﬁrst two years
following injection. Patient age, symptom type, and undifferentiated diabetes status were not predictive of treatment success.
Conclusions: Female patients presenting with their ﬁrst trigger ﬁnger have the highest rate of long-term treatment
success after a single corticosteroid injection. Patients who continue to experience symptom relief two years after
injection are likely to maintain long-term success.
Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

Peer Review: This article was reviewed by the Editor-in-Chief and one Deputy Editor, and it underwent blinded review by two or more outside experts. It was also reviewed
by an expert in methodology and statistics. The Deputy Editor reviewed each revision of the article, and it underwent a ﬁnal review by the Editor-in-Chief prior to publication.
Final corrections and clariﬁcations occurred during one or more exchanges between the author(s) and copyeditors.

T

rigger ﬁnger is one of the most common hand disorders
treated by orthopaedic surgeons, with a lifetime risk
estimated at 2.6% in the general population and 4% to
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10% in patients with diabetes1,2. Conservative treatments, including activity modiﬁcation, splinting, physiotherapy, and
non-steroidal anti-inﬂammatory drugs (NSAIDs), have been
A commentary by Mark A. Vitale, MD,
MPH, is linked to the online version of this
article at jbjs.org.
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described, but the mainstay of nonoperative treatment remains
corticosteroid injection3-6.
Prior studies have shown the success of corticosteroid
injections in the range of 61% to 84% for patients presenting
with new onset trigger symptoms after one to three injections6-14.
Increased rates of treatment failure have been correlated with
younger age, diabetes mellitus, the increased duration of
symptoms, and the presence of multiple affected digits8,9,15-17.
However, long-term success remains unknown, with the average
follow-up duration for these investigations ranging from one to
three years and the minimum follow-up duration ranging from
four to twelve months. Rozental et al. are unique in considering
the time to treatment failure with a Kaplan-Meier survival
analysis showing a nearly linear rate of symptom recurrence
within the ﬁrst year17. We are currently unable to counsel patients regarding the risk of long-term symptom recurrence after
corticosteroid injection and do not know whether the pattern of
time to treatment failure noted by Rozental et al. would continue
to gradually deteriorate or plateau beyond one year17.
The purposes of this investigation were to determine the
long-term effectiveness of a single corticosteroid injection for
trigger ﬁnger, to quantify factors impacting treatment success,
and to examine the rate of treatment failure in a Kaplan-Meier
analysis up to ten years after injection. Our hypothesis was that
diabetes mellitus and the presence of multiple trigger ﬁngers
would be associated with lower rates of success ﬁve or more
years after treatment.
Materials and Methods

T

his retrospective case series was initiated following institutional review board
approval. Trigger ﬁnger injections performed from January 2000 to December 2007 were eligible for inclusion, providing a minimum potential followup duration of ﬁve years from the time of study initiation (including telephone
follow-up for the purpose of this study). The lack of electronic patient health
records prohibited the analysis of injections prior to 2000. Patients were identiﬁed from a search of the departmental billing database for Current Procedural
Terminology (CPT) codes 20550 (injection; tendon sheath, ligament), 20551
(injection; tendon origin/insertion), and 20600 (arthrocentesis, aspiration, or
injection) associated with International Classiﬁcation of Diseases, Ninth Revision
(ICD-9) codes 727.03 (trigger ﬁnger) or 727.05 (tenosynovitis; hand, wrist).
Corticosteroid injection for trigger ﬁnger was conﬁrmed in all cases by manual
chart review. Once selected on the basis of corticosteroid injection, no attempt
was made to control for prior treatment other than injection. Patients were seen,
were diagnosed, and were injected by one of four fellowship-trained hand surgeons at our tertiary medical center (R.D.W., N.C.F., R.H.G., and R.P.C.). The
injection protocol at our institution, and the likely method used on patients in
this study, involves injection at the A1 pulley angling 45° distally and consists of
1 mL of 40-mg/mL Depo-Medrol (methylprednisolone acetate) and 0.5 to 1 mL
of 1% lidocaine without epinephrine.
Only patients with a complete ofﬁce note in the electronic medical record
system were eligible for the study. Patient age, sex, date of injection, digit injected,
18
presenting symptoms graded according to the Green classiﬁcation (Table I),
presence of multiple trigger ﬁngers, and presence of diabetes at the time of
injection were recorded. The initial study design did not differentiate between
insulin-dependent and non-insulin-dependent diabetes; thus, both types were
combined under the term “undifferentiated diabetes.” The presence of multiple
trigger ﬁngers was deﬁned as more than one symptomatic digit at the time of
injection or a history of trigger digits in the past. For patients with multiple
documented injections within the seven-year period, only the ﬁrst injection was
considered eligible to ensure that all injections were independent. For patients
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TABLE I The Green Classiﬁcation of Trigger Finger Symptoms
Grade I

Pain or tenderness at the A1 pulley

Grade II

Catching but can actively extend digit

Grade III

Locking, requiring passive extension

Grade IV

Fixed ﬂexion contracture

receiving simultaneous injections in several digits, only the ﬁrst digit listed in the
ofﬁce note was considered. This decision was made to minimize bias that could
be introduced by the selection of digit according to the duration of symptoms, the
severity of symptoms, or the digit number. Exclusion criteria after initial chart
review included prior injection or surgery of the digit, injection for diagnoses
other than trigger ﬁnger, or failure to specify which digit was injected. Patients
with additional hand conditions such as carpal tunnel syndrome or degenerative
joint disease were not excluded from the study.
The records of the remaining patients were examined for our primary
outcome of treatment failure, deﬁned as subsequent injection or surgical trigger
ﬁnger release of the affected digit. Success was determined when, at the time of
subsequent follow-up visits, ofﬁce notes did not document recurrent or persistent trigger symptoms or any additional treatment for trigger ﬁnger for patients.
Patients without recorded evidence of treatment failure or a follow-up visit in
2012 to 2013 were contacted by telephone. These patients were verbally queried
regarding recurrence of trigger ﬁnger symptoms and dates of any further treatment of the affected digit. All study participants contacted by phone provided
verbal consent for study participation. This telephone follow-up call was conducted to minimize bias toward higher estimated rates of treatment failure if our
outcomes were solely determined from ofﬁce follow-up, as patients who experience symptomatic resolution are not instructed to schedule routine follow-up
visits in our practice. Alternatively, counting all patients who did not return to the
ofﬁce as presumed treatment successes would have biased toward falsely inﬂated
rates of success had these patients not been called.
All patients with treatment failure or at least ﬁve years of follow-up were
included in the study. Patients were considered lost to follow-up if we were
unable to reach them by telephone after four attempts on separate days. Patients
were excluded after telephone call attempts if they declined participation, had
died, experienced cognitive impairment that would prohibit study consent, or
had subsequent ofﬁce notes detailing an injection without specifying the digit,
or if they stated that they received a later treatment but could not recall an
approximate date within one month.

Statistical Analysis
The overall data were examined by descriptive statistics for the frequencies in
percentages of categorical variables and means and standard deviations for
continuous variables. Univariate analysis with the chi-square test for categorical
variables or the independent t test for continuous variables was conducted to
determine success status according to independent predictors. Kaplan-Meier
analyses with the log-rank test were used to assess the difference in time to treatment failure for the categorical baseline variables. Participants without treatment
failure were censored and were removed from the Kaplan-Meier analysis at the
time point corresponding to their most recent ofﬁce visit or telephone follow-up, as
outcome data were unavailable beyond this point. Cox regression analysis was used
to determine the impact of independent variables and all possible interactions
between variables on time to treatment failure. Any signiﬁcant interaction term
(p < 0.05) was stratiﬁed in the ﬁnal multivariable Cox regression model.
Exploratory subgroup analysis according to diabetic status (insulindependent or non-insulin-dependent) was performed with chi-square analysis
testing for difference in success.

Source of Funding
No external funding was provided for this study.
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Fig. 1

Flow diagram of study enrollment.

Results
search of the departmental database identiﬁed 1049 injections in 867 patients over the speciﬁed date range. An initial
screening determined that 617 injections in 617 patients were
eligible for the study. One hundred and forty-two patients were
subsequently excluded after chart review (injections for diagnoses other than trigger ﬁnger, prior injection of the digit, digit
injected not speciﬁed, prior surgery on the digit, and injection
with planned release). Of the remaining 475 potential study
participants, 366 completed follow-up with no missing data and
were included in the ﬁnal analysis (366 injections) (Fig. 1).
Two hundred and forty patients (65.6%) were female,
with an average age (and standard deviation) of 59.2 ± 11.4
years (range, nineteen to ninety-two years). One hundred and
sixty-one patients (44.0%) had multiple trigger ﬁngers and
eighty-eight patients (24.0%) were diabetic at the time of injection. Digits injected included 137 thumbs (37.4%), ninetyeight long ﬁngers (26.8%), eighty-ﬁve ring ﬁngers (23.2%),
thirty-one index ﬁngers (8.5%), and ﬁfteen small ﬁngers
(4.1%). The symptom types of injected digits were seventy
Green Grade I (19.1%), 217 Green Grade II (59.3%), and seventynine Green Grade III (21.6%). There were no Green Grade-IV
digits among the study participants, as statically locked trigger
ﬁngers typically undergo early operative release.
Two hundred patients (54.6%) had treatment failure
requiring repeat injection or surgical release, and 166 patients
(45.4%) did not require treatment between injection and study
data collection. Seven patients (1.9%) reported no symptom
relief from the initial injection and were counted as immediate
treatment failure. Of the 200 patients with treatment failure,
128 (64%) required repeat injection and sixty-ﬁve (33%)

A
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proceeded to operative trigger release; these sixty-ﬁve patients
were 18% of all patients in the study. The median time to
treatment failure was forty-ﬁve months, and the time from
injection to study data collection for asymptomatic digits
ranged from sixty-two to 158 months. Of the 165 subjects with
telephone follow-up, 150 (90.9%) reported treatment success.
Treatment success differed between sexes, with 118 female patients (49.2%) and forty-eight male patients (38.1%)
requiring no subsequent injection or surgery (p < 0.05). One
hundred and four patients (50.7%) without multiple trigger
ﬁngers and sixty-two patients (38.5%) with multiple trigger
ﬁngers had treatment success (p < 0.05). Neither patient age
(p = 0.45) nor symptom type (p = 0.44) impacted the likelihood of injection success. Undifferentiated diabetes status did
not alter outcomes with 125 patients without diabetes (45.0%)
and forty-one patients with diabetes (46.6%) reporting treatment success (p = 0.79).
The Kaplan-Meier curve displays overall time to treatment failure for study participants (Fig. 2). Of the treatment
failures, 54.5% occurred within one year and 83.6% occurred
within two years.
The Appendix shows the Kaplan-Meier curve comparing
patients with undifferentiated diabetes and those without diabetes. Log-rank analysis failed to show a signiﬁcant difference in
time to treatment failure between these two groups (p = 0.62).
Log-rank analysis comparing sexes showed a nonsigniﬁcant difference (p = 0.06) in time to treatment failure
favoring increased success in women. The presence of multiple
trigger ﬁngers was associated with shorter time to treatment
failure (p < 0.05). However, Cox regression analysis demonstrated a signiﬁcant interaction between these two variables (p < 0.05). Therefore, an interaction term was stratiﬁed
in the ﬁnal multivariable Cox regression model. Diabetes status
was also included in the ﬁnal model because of its hypothesized
clinical impact based on prior studies.
The ﬁnal multivariable Cox regression model showed a
signiﬁcant difference in time to treatment failure for the interaction term of sex and multiple trigger ﬁngers (p < 0.05) and
no difference for undifferentiated diabetes status (p = 0.44).
Kaplan-Meier curves were constructed comparing time to

Fig. 2

Kaplan-Meier curve of overall injection success for all study participants.
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TABLE II Treatment Success Rates by Sex and Number of Trigger Fingers
Single Trigger Finger*
Time

Male

Multiple Trigger Fingers*

Female

Male

Female

At one year

59% (46% to 69%)

80% (73% to 86%)

71% (57% to 81%)

64% (54% to 73%)

At three years

46% (34% to 57%)

61% (53% to 69%)

48% (35% to 60%)

44% (34% to 53%)

At ﬁve years

41% (29% to 53%)

59% (50% to 67%)

41% (29% to 54%)

40% (30% to 49%)

At ten years

35% (23% to 48%)

56% (46% to 64%)

37% (24% to 49%)

39% (29% to 48%)

*The values are given as the average success rate, with the 95% CI in parentheses.

Fig. 3

Kaplan-Meier curve of time to treatment failure by sex for patients with their
ﬁrst trigger ﬁnger.

treatment failure by sex for both patients with their ﬁrst trigger
digit (Fig. 3) and patients with multiple trigger digits (see
Appendix). Table II displays the one, three, ﬁve, and ten-year
treatment success rates and 95% conﬁdence intervals (CIs) for
these groups. Thus, the highest chance of long-term symptomatic relief from a single corticosteroid injection for a trigger
ﬁnger is in a female patient with a single trigger ﬁnger.
Exploratory analysis according to diabetic type revealed
that our study included thirty-nine insulin-dependent patients
and forty-nine non-insulin-dependent patients. The ultimate
success rate was 35.9% for insulin-dependent patients (fourteen patients) and 55.1% for non-insulin-dependent patients
(twenty-seven patients).
Discussion
his retrospective case series evaluated the long-term efﬁcacy of corticosteroid injection for trigger ﬁnger and attempted to identify factors that may alter treatment success.
Overall, 45% of patients experienced long-term treatment
success after a single injection. Age, symptom type, and diabetes status were not predictive of treatment success. Our regression analysis identiﬁed a signiﬁcant interaction between
sex and number of trigger ﬁngers (ﬁrst or multiple), indicating
that it is inappropriate to consider either variable in isolation as
predictors of treatment success. This ﬁnding suggests that female patients may have an inherently better prognosis than

T

male patients, but the presence of multiple trigger ﬁngers erases
this protective effect. At this time, it is not clear why isolated
trigger ﬁngers in female patients responded better to initial
injection than the same condition in male patients. Eighty-four
percent of treatment failures occurred within the ﬁrst twentyfour months, suggesting that patients who continue to experience symptom relief two years after treatment are likely to
maintain long-term success.
The overall treatment success of the present study was
lower than that previously reported in the literature. Rhoades
et al. found a 72% success rate after one injection, with a mean
follow-up duration of twenty-ﬁve months (range, six to sixty
months)9. Marks and Gunther reported a success rate of 84%
for trigger ﬁngers and 92% for trigger thumbs after a single
injection with a mean follow-up duration of forty-one months
(range, twelve to 104 months)13. The higher treatment success
of these studies may be explained by the shorter minimum
follow-up time, as our data show that treatment failures are
frequently within the ﬁrst two years after injection. Other
studies permitted a second or third injection several weeks
later in patients who failed to respond to the ﬁrst injection but
deﬁned failure more broadly to include any symptom recurrence. Using such methodology, Faunø et al. found a 76%
success rate at a follow-up duration of three to ﬁfteen years,
with only 35% of patients reporting symptom resolution after
one injection12. Similarly, Newport et al. reported a 77% success
rate at an average follow-up duration of thirty-ﬁve months,
with only 49% improving after a single injection8. By deﬁning
treatment failure as repeat injection or surgery, our rates of
success would be expected to be higher, as mild symptom
persistence did not necessitate categorization as failure.
The association between age and treatment success is debated. Faunø and colleagues showed no association between age
and treatment success in their long-term study of 104 digits12.
However, more recently, Rozental et al. reported increased rates of
treatment failure in younger patients17. Considering our data in light
of the report by Rozental et al. that concluded follow-up at one year,
it is possible that age plays a role in short-term, but not long-term,
treatment success. Consistent with prior studies, we found no
correlation between symptom type and prognosis following injection8,17. Our ﬁnding of multiple trigger ﬁngers as a predictor of
poorer outcomes is consistent with several prior works6,8,9,17.

1853
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
V O LU M E 96 -A N U M B E R 22 N O V E M B E R 19, 2 014
d

d

d

L O N G -T E R M O U T C O M E S F O L L O W I N G A S I N G L E
CORTICOSTEROID INJECTION FOR TRIGGER FINGER

TABLE III Potential Impact of Patients Lost to Follow-up on Overall Success Rate
Loss to Follow-Up
Theoretical Success
Rate*
0%

Impact on Overall Data

Theoretical Additional
Successes†
0

Adjusted Total
Successes†
166

Adjusted Total
Patients†

Adjusted Success
Rate*

435

38.2%

50%

34.5

200.5

435

46.1%

90.9%‡

62.7

228.7

435

52.6%

69

235

435

54%

100%

*The values are given as the rates of success in percentages. †The values are given as the number of patients. ‡The rate of success was based
on participants who were contacted by telephone in this study.

The literature on diabetes and steroid injection for trigger ﬁnger continues to evolve. Early studies found no relationship between treatment success and associated disease
processes, including diabetes9,12. More recent studies looking
speciﬁcally at diabetic patients have concluded that this patient
population is at heightened risk for symptom recurrence and
subsequent intervention. Griggs et al. reported a 50% success rate among a diabetic population at an average follow-up
of twenty-seven months with worse outcomes in insulindependent patients with diabetes (44%) than in non-insulindependent patients with diabetes (71%)2. Stahl and colleagues
found 49.2% success in diabetics compared with 76.3% in a
control group of non-diabetics at four-month follow-up15. A
randomized controlled trial by Baumgarten et al. concluded
that patients with diabetes responded less favorably after a twoinjection treatment and were more likely to require surgery
than patients without diabetes at thirteen to forty-one months
follow-up, although they found no difference in outcome between the groups after a single injection16. However, none of
these studies controlled for the potential confounding factor of
multiple trigger ﬁngers, which had a higher incidence among
patients with diabetes in all studies. Our own Cox regression
model found no signiﬁcant difference between patients with
diabetes and patients without diabetes despite being adequately
powered. We did not design this study to differentiate between
patients with insulin-dependent diabetes and those with noninsulin-dependent diabetes, but we did perform an exploratory
analysis that suggested that insulin dependence may impact
injection success2,15,17. Despite enrolling nearly 400 patients, our
study remained underpowered to incorporate diabetic categories according to insulin dependence into our Kaplan-Meier
analysis.
Similar to the investigation by Rozental and colleagues17,
our Kaplan-Meier analysis demonstrated a nearly linear rate of
treatment failure during the ﬁrst year after injection. However,
the longer-term follow-up in our present study indicates
that this rate decreases substantially after one year, nearly
reaching a plateau by two years. This ﬁnding suggests that,
in many patients, a single injection may be sufﬁcient to alter
local biology of disease and to prevent symptom recurrence
indeﬁnitely.

Completion of this study required several methodologic choices and compromises that deserve consideration.
First, we only looked at time to repeat injection or surgery,
not recurrence of symptoms, which is difﬁcult to assess retrospectively. Therefore, patients with recurrent symptoms
who did not seek further treatment are categorized as successes in our study. Although this deﬁnition of treatment
failure was necessary, we believe that it was an appropriate
measure as we captured clinically relevant symptoms sufﬁcient to prompt further treatment. At the same time, we did
not control for any adjunct treatments such as splinting,
therapy, or NSAIDs. Second, chart review alone selects for
patients who returned with symptom recurrence and would
bias the study toward higher rates of treatment failure. We
attempted to mitigate this by calling patients who did not
have sufﬁcient follow-up time in the chart. Nevertheless,
sixty-nine patients were lost to follow-up, and thus our study
may have underestimated the true rate of treatment success as
91% of those who did not return to the ofﬁce after injection
reported treatment success when contacted by telephone. On
the basis of a sensitivity analysis, we estimated that an adjusted success rate for the entire population may approach
53% compared with our calculated 45%, assuming a success
rate among the sixty-nine participants lost to follow-up,
consistent with those who were contacted by telephone (Table
III). Third, we did not consider two or three-injection regimens for initial treatment of trigger ﬁnger. By considering
only a single injection, our study design allows patients and
physicians to estimate the chance that a single injection for
trigger ﬁnger at initial presentation will resolve the condition
to a degree that further injections or surgery will not be
needed. Finally, in the event of multiple presenting trigger
ﬁngers, we analyzed only data from the ﬁrst digit noted in the
record. This was chosen to capture the chief symptom for the
ofﬁce visit as opposed to secondary trigger ﬁngers identiﬁed
during examination. Multiple digits from individual patients
were not analyzed to keep each trigger digit as a truly independent event during statistical analysis.
Our study had several limitations. We did not have
data on treatment sought by patients with an outside provider. Patients were asked by telephone if they required any
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further treatment, but it is possible that we were still unable
to fully account for injections or surgery performed elsewhere secondary to recall bias. We also did not consider
adjunctive treatments such as splinting, hand therapy, or
oral medication prior to or after injection. However, this
should not bias our results as patients are not routinely
prescribed such treatments following injection and it is
unlikely any patient group independently sought these adjuncts more than others. Additionally, this study did not
evaluate outcomes in patients who had received prior injections, which is a group of patients for which optimal
treatment remains controversial.
This study lends further support to the use of corticosteroid injection as the initial treatment in patients presenting
with new onset trigger ﬁnger. It is our hope that patients and
clinicians can utilize these data to make more informed treatment decisions and to set reasonable expectations regarding the
need for future treatment following injection.
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Appendix
Figures showing Kaplan-Meier curves of time to treatment failure by diabetic status and by sex for patients with
multiple trigger ﬁngers are available with the online version of
this article as a data supplement at jbjs.org. n
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